Abstract:In 2022, the US National Institute on Drug Abuse reported that there were 81 806 deaths related to opioids, a 64% increase between 2019 and 2022. 1 Of concern are people experiencing homelessness (PEH), who have 12 times the risk of drug overdose mortality compared with the general US population. 2 Although medications to treat opioid use disorder (OUD), such as buprenorphine, are effective and safe, PEH are less likely to receive these treatments due to patient-, clinician-, and system-level barriers. 3 Although delivery of medication for OUD treatment through office-based addiction treatment programs has been reported to reduce all-cause mortality, 4 PEH experience unique barriers that prevent them from continuing addiction treatment at brick-and-mortar clinics. A shelter-based opioid treatment (SBOT) program provides an alternative approach to improve access to medications for OUD (eg, buprenorphine) by delivering on-site care at a family shelter for PEH. Initial findings on a SBOT program in Boston, Massachusetts, 5 reported that this type of program reduced illicit substance abuse, reduced opioid overdose, and improved employment. However, the value assessment (eg, cost-effectiveness) and affordability (eg, budget impact) of SBOT programs have yet to be ascertained and are important factors for decision-making. In their study, Chatterjee et al 6 evaluated the cost-effectiveness and budget impact of SBOT for PEH from the US health care and societal perspectives. Using dynamic state-transition models, Chatterjee et al 6 reported that SBOT for PEH was not only cost-effective over the lifetime horizon, but also affordable to health care payers and society over a 10-year period, despite the expected increase in costs due to offsets by averted incarcerations, overdoses, and deaths. Pharmacoeconomic models are useful for policymakers who struggle with limited information to make informed decisions about public health. In particular, the intersection between homelessness and OUD is a complicated and challenging public health crisis that requires careful synthesis of the available data. Given that no long-term study is available on opioid treatment among PEH, simulations such as the one developed by Chatterjee et al 6 provide valuable projections on the clinical and economic benefit of public health interventions. However, models may not capture all the relevant scenarios or conditions, particularly with PEH and OUD, and policymakers will need to consider other factors when making decisions about optimal strategies to address the opioid crisis among PEH. PEH encounter more barriers to receiving treatment for OUD than those who are housed; however, once receiving treatment, PEH experience similar clinical benefits. 3 Therefore, reducing barriers to access is an important public health strategy to mitigate opioid-related morbidity and mortality among PEH. By delivering addiction treatment to the shelters where PEH are staying, SBOT has an advantage over other forms of interventions, such as brick-and-mortar treatment centers. However, several issues persist despite evidence supporting implementation and sustainability of SBOT for PEH, such as addressing the root cause of the problem, adherence and retention in treatment, and location of SBOT programs. According to a report by the National Alliances to End Homelessness based on data from the US Department of Housing and Urban Development, 7 the estimated prevalence of PEH and those living in shelters have increased by 6% between 2017 and 2022. There is debate regarding the association of homelessness with OUD, which may unfairly lay blame on PEH and detract from the actual conversation of finding and implementing solutions. According to Doran et al, 8 the underlying association of opioid addiction with PEH appears to be bidirectional and arguments for a unidirectional association only further stigmatization of a marginalized population. What is known is that a lack of housing is significantly associated with opioid-related deaths. For instance, Bradford et al 9 reported that a 1% increase in homelessness was associated with an increase of 68 opioid-related deaths in a metropolitan continuum-of-care area. Stable housing is an important factor in the comprehensive OUD treatment paradigm for PEH. Without stable housing, there is a higher likelihood of treatment interruption, relapse, and death. To effectively address OUD among PEH, policymakers will need to tackle both housing and OUD treatment. This requires commitment and coordination by local government and public health agencies to implement housing programs (eg, Housing First) and expansion of addiction treatment services to address OUD for PEH. Another concern is adherence and retention with OUD treatment among PEH. Adherence with office-based -Abstract Truncated-

Rural houselessness among people who use drugs in the United States: Results from the National Rural Opioid Initiative

Correlates of overdose among 2711 people who use drugs and live in 7 rural US sites

A cross-sectional survey of potential factors, motivations, and barriers influencing research participation and retention among people who use drugs in the rural USA

Overdose responses among rural people who use drugs: A multi-regional qualitative study

The Impact of the COVID-19 Pandemic on Drug Use Behaviors, Fentanyl Exposure, and Harm Reduction Service Support among People Who Use Drugs in Rural Settings

Barriers to opioid use disorder treatment among people who use drugs in the rural United States: A qualitative, multi-site study

Using drugs alone in single room occupancy housing: Understanding environmental drivers of overdose risk

The War on Drugs, Racialized Capitalism, and Health Care Utilization Among White People Who Use Drugs in 22 Rural Appalachian Counties

Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry

Addressing the Spectrum of Opioid Misuse Prevention, Treatment, and Recovery in Rural Washington State Communities: Provider Identified Barriers and Needs

Community Perceptions of Comprehensive Harm Reduction Programs and Stigma Towards People Who Inject Drugs in Rural Virginia

Behavioral and Health Outcome Differences by Heroin or Methamphetamine Preference Among People in Rural US Communities Who Use Both Substances

The Rural Opioid Initiative Consortium description: providing evidence to Understand the Fourth Wave of the Opioid Crisis

Value of Shelter-Based Opioid Treatment Among People Experiencing Homelessness

Opioid Overdoses and Take-Home Naloxone Interventions: Ethnographic Evidence for Individual-Level Barriers to Treatment of Opioid Use Disorders in Rural Appalachia

Identifying Areas with Disproportionate Local Health Department Services Relative to Opioid Overdose, HIV and Hepatitis C Diagnosis Rates: A Study of Rural Illinois

Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont

Drug Overdose Mortality Among People Experiencing Homelessness, 2003 to 2018

Racialized environments and syringe services program implementation: County-level factors

The impact of the COVID-19 pandemic on people who inject drugs accessing harm reduction services in an rural American state

Impact of COVID-19 on rural and nonrural recovery housing in the United States.